In:
American Journal of Hematology, Wiley, Vol. 45, No. 2 ( 1994-02), p. 128-135
Abstract:
Topical bovine thrombin preparations are used extensively in cardiovascular, neurosurgical, and otolaryngologic procedures. Patients who are treated with these topical thrombin preparations may develop antibodies to bovine coagulation factors that may cross‐react with the endogenous human clotting proteins. We have identified four patients with acquired factor inhibitors following exposure to topical thrombin at Duke University Medical Center and summarize these cases in addition to 13 patients previously reported in the literature. In most cases, the inhibitor developed following a second (or subsequent) exposure to topical thrombin. The clinical course was extremely variable, ranging from totally asymptomatic to life‐threatening hemorrhage. The most consistent laboratory abnormality was a prolonged bovine thrombin clotting time, which corrected, at least partially, when human thrombin was substituted for bovine thrombin. Some of these patients also developed factor V inhibitors with prolonged prothrombin and activated partial thromboplastin times. Although these patients have prolonged clotting times, they should not be considered “autoanticoagulated,” since thromboembolic complications can still occur. Therapeutic intervention is largely empirical and depends on the clinical manifestations of the individual patient. © 1994 Wiley‐Liss, Inc.
Type of Medium:
Online Resource
ISSN:
0361-8609
,
1096-8652
DOI:
10.1002/ajh.2830450206
Language:
English
Publisher:
Wiley
Publication Date:
1994
detail.hit.zdb_id:
1492749-4
